Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency (EXUROC)

18. November 2026 aktualisiert von: Kristoffer Rohrberg

EXUROC Bladder Target - LP-184, an Acylfulvene, for PTGR1-positive, DNA Repair-deficient Urothelial Carcinoma. A Phase Ib/II Study of Safety, Tolerability, and Efficacy in Advanced/Metastatic Urothelial Carcinoma

This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma.

LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug.

The study aims to investigate whether LP-184 can be safely administered and whether it can reduce tumor growth in patients whose tumors have these specific characteristics.

The study consists of two parts. Phase Ib will evaluate the safety and tolerability of LP-184 and determine the recommended dose for Phase II. Phase II will investigate the antitumor activity of LP-184 by assessing tumor response to treatment.

All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. Up to 39 patients will be enrolled in the study.

Studienübersicht

Detaillierte Beschreibung

EXUROC Bladder Target is an investigator-initiated, single-center, open-label, single-arm Phase Ib/II clinical trial evaluating the safety, tolerability, and antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma (UC) selected by PTGR1 positivity and DNA damage repair (DDR) deficiency.

LP-184 is a next-generation semisynthetic acylfulvene that acts as a prodrug requiring intracellular activation by prostaglandin reductase 1 (PTGR1). Following activation, LP-184 induces DNA damage that may be particularly cytotoxic to tumor cells with deficiencies in DNA repair pathways, including nucleotide excision repair (NER) and homologous recombination (HR). Preclinical studies have demonstrated enhanced sensitivity to acylfulvenes in tumors with impaired DNA repair mechanisms, providing the rationale for biomarker-based patient selection.

The study consists of two sequential phases:

Phase Ib: The first part will evaluate the safety and tolerability of LP-184 and determine the recommended Phase II dose (RP2D). A modified 3+3 dose de-escalation design will be applied, starting at 0.39 mg/kg, with predefined lower dose levels of 0.31 mg/kg and 0.25 mg/kg if dose-limiting toxicities (DLTs) occur. Safety and tolerability will be assessed, and dose de-escalation decisions will be based on observed toxicities.

Phase II: The second part will evaluate the antitumor activity of LP-184 at the RP2D using a Simon's two-stage minimax design. A total of 27 patients will contribute to the Phase II evaluation, including eligible patients treated during Phase Ib. The design allows for early termination if insufficient antitumor activity is observed during the first stage.

LP-184 will be administered intravenously on days 1 and 8 of each 21-day cycle. Treatment may continue for up to one year unless disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria occur.

Tumor response will be evaluated using RECIST version 1.1, and treatment-related adverse events will be assessed using CTCAE version 5.0. Quality of life will be assessed using the EORTC QLQ-C30 questionnaire.

The study aims to determine whether selecting patients based on PTGR1 expression and DDR deficiency can identify a population that may benefit from LP-184 treatment, potentially supporting further clinical development of this biomarker-driven therapeutic strategy.

Studientyp

Interventionell

Einschreibung (Geschätzt)

39

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Copenhagen, Dänemark, 2100
        • Rigshospitalet, Phase 1 Unit, Department of Oncology, Section 5073. Address: Blegdamsvej 9, 2100 Copenhagen, Denmark

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Provide signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling, and analyses.
  • Histologically confirmed progressive, advanced (T4b, N+ or M1) urothelial carcinoma (UC)
  • Measurable disease by RECIST 1.1
  • DDR deficiency by local test
  • PTGR1 overexpression as defined by local test
  • ECOG performance status 0-1
  • Minimum age of 18 years
  • Life expectancy > 3 months
  • No prior treatment with acylfulvenes
  • At least one prior line of systemic treatment. Patients ineligible for standard second-line treatment may be considered for inclusion.
  • At least 4 weeks after major surgery or radiotherapy. Short-duration, limited-field radiotherapy for symptom control is allowed until 2 weeks before C1D1.
  • Adequate organ function at screening defined as:
  • Liver Function:

AST*, ALT* ≤3 × ULN or <5 × ULN in cases of documented liver metastases or involvement of the liver in the disease process.

Total serum bilirubin* ≤1.5 × ULN or <5 × ULN if secondary to Gilbert's Syndrome or documented liver metastases or involvement of the liver in the disease process.

•Renal Function: Serum creatinine clearance ≥45 mL/min either measured or calcu-lated using the standard Cockcroft-Gault formula.

•Bone Marrow Function:ANC* ≥1,5 × 10⁹/L. Hemoglobin* ≥5,0 mmol/L (The use of transfusion or other interven-tion to achieve hemoglobin ≥5,0 mmol/L is acceptable. For those pa-tients undergoing RBC transfusion, hemoglobin must be evaluated at least 14 days after the last RBC transfusion).

Platelet count* ≥100 × 10⁹/L (assessed ≥7 days following last platelet transfusion in patients with thrombocytopenia requiring platelets).

•Blood clotting function: INR* and aPTT* ≤1.5 × ULN. Patients on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for the intended use.

Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days of the first dose of LP-184. A woman is of child bearing potential unless she:

  • has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy.
  • is aged ≥60 years and is amenorrhoeic.
  • is aged <60 years and has been amenorrhoeic for ≥12 months (including no irregular menses or spotting) in the absence of any medication which induces a meno-pausal state and has documented ovarian failure by serum estradiol and follicle-stimulating hormone.

Women of childbearing potential must use highly effective contraception. Men of reproductive potential must agree to use highly effective contraceptive methods and avoid sperm donation during the study treatment and for 3 months after the last dose of LP-184. A man is of reproductive potential unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.

Regarding brain metastases, based on one of the following:

  • No clinical evidence of brain metastases.
  • Previously treated brain metastases that are either stable for at least 4 weeks since last treatment or progressed since prior local CNS therapy and not requiring imme-diate re-treatment with local therapy.
  • Patients on a chronic stable dose of ≤2 mg total daily of dexamethasone (or equivalent) are eligible.

Exclusion Criteria:

  • Exposure to anti-cancer therapy within 2 weeks or within at least 5 half-lives of the anti-cancer agent whichever is shorter; or 4 weeks from any biologics/immunotherapies or any investigational therapy prior to the first dose of LP-184. (Note: low-dose steroids (oral prednisone or equivalent ≤20 mg/day), localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer, and treatment with bisphosphonates and RANKL inhibitors are not criteria for exclusion if such therapy has not been changed within 4 weeks before LP-184 treatment.)

  • Any history of retinopathy and/or macular degeneration (without specifications or grades).

  • Infection requiring antibiotics, antivirals, or antifungals within 1 week prior to first dose of study drug. Prophylactic therapy for e.g. urinary tract infections allowed.

  • Hepatitis B and/or hepatitis C infection (determined on baseline hepatitis B and C screen) or known seropositivity for or history of active viral infection with human immunodeficiency virus (HIV).

  • Have clinically significant cardiac disease including:

    • New York Heart Association Class IV heart failure.
    • Myocardial infarction or stroke ≤3 months prior to the first dose of LP-184.
    • Unstable angina within ≤12 weeks prior to the first dose of LP-184 unless the underlying disease has been corrected by procedural intervention e.g., stent, bypass.
    • Severe aortic stenosis.
    • Uncontrolled arrhythmia.
    • QTc >470 milliseconds by Fridericia criteria.
    • Congenital long QT syndrome, or a QTcF interval >470 ms (average of triplicate ECGs) at screening and on Cycle 1 Day 1 (pre-dose) except for a documented bundle branch block or unless secondary to a pacemaker.
  • Have clinically significant AEs that have not resolved to baseline or ≤Grade 1 based on NCI-CTCAE prior to first dose of study drug, unless approved by the sponsor. Patients with chronic Grade 2 toxicities may be eligible at the discretion of the investigator, e.g. Grade 2 chemotherapy-induced neuropathy, alopecia, or hypothy-roidism from prior immunotherapy treatment).

  • Have any other serious medical condition which, in the opinion of the investigator, would preclude the patient from study participation.

  • Pregnant or breastfeeding women, or women of childbearing potential unwilling or unable to comply with contraception requirements.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: LP-184 arm

All participants will receive LP-184 intravenously on days 1 and 8 of each 21-day treatment cycle. In Phase Ib, a modified 3+3 dose de-escalation design will be used to determine the recommended Phase II dose (RP2D). In Phase II, participants will receive LP-184 at the established RP2D.

LP-184 is an investigational semisynthetic acylfulvene administered intravenously on days 1 and 8 of each 21-day cycle. In Phase Ib, the starting dose is 0.39 mg/kg, with predefined dose de-escalation levels of 0.31 mg/kg and 0.25 mg/kg. In Phase II, LP-184 will be administered at the recommended Phase II dose (RP2D) established during Phase Ib. Treatment may continue for up to one year or until disease progression, unacceptable toxicity, or other protocol-defined discontinuation criteria.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Dose-Limiting Toxicity
Zeitfenster: During the first treatment cycle (21 days).

Number and proportion of participants experiencing dose-limiting toxicities (DLTs) associated with LP-184 treatment, assessed according to the protocol-defined DLT criteria and graded using CTCAE version 5.0.

During the first treatment cycle (21 days).
Recommended Phase II Dose (RP2D) of LP-184
Zeitfenster: During Phase Ib dose evaluation, up to approximately 6 months

Determination of the recommended Phase II dose (RP2D) of LP-184 based on observed dose-limiting toxicities and overall safety and tolerability during Phase Ib.

During Phase Ib dose evaluation, up to approximately 6 months
Objective Response Rate (ORR) According to RECIST Version 1.1
Zeitfenster: From treatment initiation until disease progression or end of treatment, up to 1 year.

Proportion of participants achieving a complete response (CR) or partial response (PR) as their best overall response, assessed according to RECIST version 1.1.

From treatment initiation until disease progression or end of treatment, up to 1 year.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression-Free Survival (PFS)
Zeitfenster: From initiation of LP-184 treatment until the first documented disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Time from initiation of LP-184 treatment to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

From initiation of LP-184 treatment until the first documented disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.
Overall Survival (OS)
Zeitfenster: From initiation of LP-184 treatment until death from any cause or last follow-up, assessed up to approximately 18 months.

Time from initiation of LP-184 treatment to death from any cause.

From initiation of LP-184 treatment until death from any cause or last follow-up, assessed up to approximately 18 months.
Duration of Response (DoR)
Zeitfenster: From the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Time from the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, among participants achieving an objective response according to RECIST version 1.1.

From the first documented complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurs first, assessed up to approximately 18 months.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

30. November 2026

Primärer Abschluss (Geschätzt)

1. November 2029

Studienabschluss (Geschätzt)

1. November 2031

Studienanmeldedaten

Zuerst eingereicht

3. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

18. November 2026

Zuerst gepostet (Tatsächlich)

20. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

18. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data are not currently planned to be shared with external researchers.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren